Drug Subsidies & Schemes 

Tags:

The Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics (SOCs) and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.

Subsidies and financial assistance are given for drugs approved under the Standard Drug List (SDL) and Medication Assistance Fund (MAF). Drugs approved under the SDL and MAF must be registered with the Health Sciences Authority (HSA) and assessed to be clinically- and cost-effective. MAF drugs are generally newer and more expensive, and therefore MAF applies only when these drugs are used for suitable clinical indications so that MAF drugs are appropriately used. In exceptional cases, MAF can also support HSA-registered drugs that are not on the SDL or MAF list, on a case-by-case basis.

The drugs listed on this page are reviewed and updated on a regular basis by MOH to take into account changes in clinical practice, advances in medical science, and the evolving needs of patients. Should you require further clarification about your medications, please consult your physician or pharmacist for assistance.

Frequently Asked Questions

Have more questions? Check out our Frequently Asked Questions on the Medication Assistance Fund.

List of Drugs* (as of 2 July 2018)

* The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors.

Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Absolute Alcohol Injection100%SDL
AcetazolamideTablet250 mgSDL
Acetic acidEar drops2%, 3%, 4%, 5%SDL
AcetylcysteineInjection2 g/10 mL, 5 g/25 mLSDL
AciclovirConcentrate for infusion250 mg/10 mLSDL
AciclovirInfusion250 mgSDL
AciclovirEye ointment3%SDL
AcitretinCapsule10 mg, 25 mgSDL
AdalimumabPrefilled pen40 mg/0.8 mLMAFChecklist to be completed.
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of juvenile idiopathic arthritis
5) Treatment of adult patients with Crohn's disease
6) Treatment of children (6 years and older) with Crohn's disease
7) Treatment of adult patients with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
AdalimumabPrefilled syringe40 mg/0.8 mLMAFChecklist to be completed.
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of juvenile idiopathic arthritis
5) Treatment of adult patients with Crohn's disease
6) Treatment of children (6 years and older) with Crohn's disease
7) Treatment of adult patients with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
Adefovir Dipivoxil Tablet10 mgSDL
AdrenalineInjection1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL)SDL
AlbendazoleOral suspension400 mg/10 mLSDL
AlbendazoleTablet400 mgSDL
Alendronic AcidTablet10 mg, 70 mgSDL
Alendronic Acid & Colecalciferol TabletAlendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international unitsMAF1) For patients with osteoporosis (T-score ≤ -2.5)
2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
AlfacalcidolCapsule0.25 mcg, 1 mcgSDL
AlfacalcidolOral drops2 mcg/mLSDL
AlfacalcidolTablet0.25 mcg, 1 mcgSDL
Alfuzosin HydrochlorideTablet10 mgSDL
Alginic Acid, Sodium Bicarbonate, Aluminium Hydroxide & Magnesium Trisilicate Chewable tabletAlginic Acid 500 mg + Sodium Bicarbonate 170 mg + Aluminium Hydroxide (dried gel) 100 mg + Magnesium Trisilicate 25 mgSDL
AllopurinolTablet100 mg, 300 mgSDL
AlteplaseInfusion50 mg/50 mLSDL
Aluminium HydroxideTablet600 mgSDL
Aluminium Hydroxide, Magnesium Trisilicate & SimeticoneChewable tabletAluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg SDL
Aluminium Hydroxide, Magnesium Trisilicate & SimeticoneOral suspensionAluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL SDL
Aluminium Oxide Oral suspension4%SDL
Amikacin Injection500 mg/2 mLSDL
Amiloride & HydrochlorothiazideTabletAmiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mgSDL
Amino AcidsInfusion5%, 10%SDL
Aminobenzoic AcidOintment10%SDL
AminophyllineInjection250 mg/10 mLSDL
Amiodarone HydrochlorideInjection50 mg/mLSDL
Amiodarone HydrochlorideTablet200 mgSDL
AmitriptylineTablet10 mg, 25 mgSDL
Amlodipine Tablet5 mg, 10 mgSDL
AmoxicillinCapsule250 mgSDL
AmoxicillinOral suspension125 mg/5 mLSDL
Amoxicillin & Clavulanic Acid InjectionAmoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mgSDL
Amoxicillin & Clavulanic Acid Oral suspensionAmoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mLSDL
Amoxicillin & Clavulanic Acid TabletAmoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mgSDL
Amphotericin BInjection50 mgSDL
Amphotericin BEye drops1 mg/mLSDL
AmpicillinInjection0.5 gSDL
AnastrozoleTablet1 mgMAFTreatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer
Antazoline Hydrochloride & Tetryzoline HydrochlorideEye dropsAntazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mLSDL
Anti-Rabies ImmunoglubulinInjection300 units/2 mLSDL
AprepitantCapsule80 mg, 125 mgMAFPrevention of chemotherapy-induced nausea and vomiting in patients receiving high dose cisplatin
AprepitantCapsule80 mg & 125 mg (Tripack)MAFPrevention of chemotherapy-induced nausea and vomiting in patients receiving high dose cisplatin
Aqueous CreamCreamEmulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%SDL
Ascorbic AcidTablet100 mgSDL
Ascorbic Acid Injection1 g/20 mL, 500 mg/5 mL SDL
AspirinTablet100 mg, 300 mgSDL
AtenololTablet50 mg, 100 mgSDL
AtorvastatinTablet10 mg, 20 mg, 40 mg, 80 mgSDL
AtracuriumInjection25 mg/2.5 mL, 50 mg/5 mLSDL
Atropine SulfateEye drops0.5%, 1%SDL
Atropine Sulfate Injection0.6 mg/mL, 6 mg/mLSDL
AzathioprineTablet50 mgSDL
Azithromycin Extended-release oral suspension2 gSDL
Azithromycin Injection500 mgSDL
Azithromycin Oral suspension200 mg/5 mLSDL
Azithromycin Tablet250 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Bacillus Calmette-GuerinSolution for intravesical use27 mg, 81 mgSDL
Bacillus Calmette-Guerin VaccineInjection0.75 mg/mLSDL
Bacitracin, Polymyxin & Neomycin PowderBacitracin Zinc 400 u/g + Polymyxin B Sulfate 5,000 u/g + Neomycin Sulfate 3,400 u/gSDL
BeclomethasoneInhaler250 mcg/doseSDL
Beclomethasone DipropionateInhaler50 mcg/doseSDL
BentoniteSuspension7%SDL
Benzalkonium Chloride & Cetrimide CreamBenzalkonium Chloride 0.01% + Cetrimide 0.2%SDL
Benzathine BenzylpenicillinInjection2.4 million international unitsSDL
BenzatropineInjection2 mg/2 mLSDL
Benzatropine Mesilate Tablet2 mgSDL
Benzhexol Hydrochloride Tablet2 mgSDL
Benzoyl PeroxideGel2.5%, 5%, 10%SDL
Benzoyl Peroxide Lotion5%, 10%SDL
Benzyl BenzoateTopical emulsion25%SDL
Benzylpenicillin SodiumEye drops (preservative-free)2,500 international units/mLSDL
Benzylpenicillin Sodium Injection1 million international units, 5 million international unitsSDL
Betahistine Mesilate Tablet6 mgSDL
Betamethasone (as Valerate) Scalp lotion0.1%SDL
Betamethasone (as Valerate) Cream0.0125%, 0.025%, 0.05%, 0.1%SDL
Betamethasone (as Valerate) Ointment0.025%, 0.05%, 0.1%SDL
Betamethasone (as Valerate) & ClioquinolCreamBetamethasone 0.025% + Clioquinol 3%, Betamethasone 0.05% + Clioquinol 3%, Betamethasone 0.1% + Clioquinol 3%SDL
Betamethasone Sodium PhosphateEye/ear drops0.1%SDL
Betamethasone Sodium PhosphateEye/ear drops0.1%SDL
BetaxololEye drops0.25%SDL
Bethanechol Chloride Tablet10 mgSDL
BevacizumabIntravitreal injection25 mg/mLMAF1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration
2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion
3) Treatment of adults with visual impairment due to diabetic macular oedema
BisacodylEnteric-coated tablet5 mgSDL
BisacodylRectal suppository10 mgSDL
Bismuth SubcitrateTablet120 mg, 300 mgSDL
Bismuth SubgallateRectal suppositoryBismuth Subgallate 200 mg + Zinc Oxide 120 mgSDL
Bismuth SubnitratePaste10%SDL
Bisoprolol Fumarate Tablet2.5 mg, 5 mgSDL
BleomycinInjection15 mgSDL
Boric Acid, Resorcinol & Phenol PaintBoric Acid 0.8% + Resorcinol 8% + Phenol 4%SDL
BortezomibInjection3.5 mgMAFChecklist to be completed.
For primary induction in newly diagnosed patients with symptomatic multiple myeloma
Botulinum toxin type A complex (Botox)Injection50 unitsMAFFor adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy
Brimonidine TartrateEye drops0.15%SDL
BromocriptineTablet2.5 mgSDL
Buclizine Hydrochloride Tablet25 mgSDL
Budesonide Powder inhaler100 mcg/dose, 200 mcg/doseSDL
Bupivacaine Hydrochloride (hyperbaric) Injection0.5% (in dextrose 8%)SDL
Bupivacaine Hydrochloride (isobaric)Injection0.5%SDL
BuprenorphineSublingual tablet0.2 mgSDL
BusulfanInjection60 mgSDL
BusulfanTablet2 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
CabergolineTablet0.5 mgMAFAs a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine
CalamineLotionCalamine 15%SDL
Calamine & MentholLotionCalamine 15% + Menthol 0.4%SDL
Calcipotriol Cream50 mcg/gSDL
Calcipotriol Ointment50 mcg/gSDL
Calcipotriol Scalp solution50 mcg/mLSDL
Calcipotriol & Betamethasone GelCalcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/gSDL
Calcipotriol & Betamethasone OintmentCalcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/gSDL
CalcitriolCapsule0.25 mcg, 0.5 mcgSDL
Calcium Syrup20 mg to 23 mg Ca2+/mLSDL
Calcium AcetateTablet667 mgSDL
Calcium CarbonateChewable tablet1.25 gSDL
Calcium CarbonateTablet625 mgSDL
Calcium Carbonate & Colecalciferol TabletCalcium Carbonate 450 mg + Colecalciferol 5 mcgSDL
Calcium Chloride Dihydrate Injection10%SDL
Calcium GluconateInjection10%SDL
Calf Blood Extract (deproteinised) Eye gel8.3 mg/gSDL
Candesartan Cilexetil Tablet4 mg, 8 mg, 16 mgMAFTreatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
CapecitabineTablet150 mg, 500 mgSDL
CaptoprilTablet12.5 mg, 25 mgSDL
CarbamazepineControlled-release tablet200 mg, 400 mgSDL
CarbamazepineSyrup100 mg/5 mLSDL
CarbamazepineTablet200 mgSDL
CarbimazoleTablet5 mgSDL
CarboplatinInjection150 mg/mL, 10 mg/mLSDL
CarmustineInjection100 mgSDL
CarvedilolTablet6.25 mg, 12.5 mg, 25 mgSDL
Cefalexin Capsule250 mgSDL
Cefalexin Oral suspension125 mg/5 mLSDL
CefazolinInjection1 gSDL
Ceftazidime Injection1 gSDL
Ceftriaxone Injection250 mg, 1 g, 2 gSDL
CetirizineSolution1 mg/mLSDL
CetrimideTopical solution1%SDL
CetrimideShampoo5%SDL
Charcoal (activated)Granules50 gSDL
Charcoal (activated)Oral suspension200 mg/mL (in sorbitol 70%)SDL
Charcoal (activated)Tablet250 mgSDL
Chloral HydrateOral solution200 mg/5 mL, 500 mg/5 mLSDL
ChlorambucilTablet2 mgSDL
ChloramphenicolCapsule250 mgSDL
ChloramphenicolEye drops0.5%SDL
ChloramphenicolEye ointment1%SDL
ChlordiazepoxideTablet5 mgSDL
Chlorhexidine Acetate Irrigation solution0.02%SDL
Chlorhexidine Gluconate Cream1%SDL
Chlorhexidine Salt Mouthwash0.2%SDL
Chlorhexidine Salt Topical solution 0.05%, 0.1% SDL
Chlorhexidine Salt Topical solution4%SDL
Chlorhexidine Salt Mouthwash0.2%SDL
Chlorhexidine Salt & AlcoholTopical solutionChlorhexidine Salt 0.1% + Alcohol 70%, Chlorhexidine Salt 0.5% + Alcohol 70%SDL
Chlorhexidine Salt & CetrimideTopical solutionChlorhexidine Salt 0.015% + Cetrimide 0.15%SDL
Chloroquine PhosphateTablet150 mgSDL
ChlorpheniramineSyrup4 mg/5 mLSDL
ChlorpheniramineTablet4 mgSDL
ChlorpromazineInjection50 mg/2 mLSDL
ChlorpromazineTablet25 mg, 100 mgSDL
ChlorpropamideTablet250 mgSDL
ChlortetracyclineEye ointment1%SDL
Choline SalicylateOral gel9%SDL
CiclosporinCapsule10 mg, 25 mg, 100 mgSDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CiclosporinOral solution100 mg/mLSDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CimetidineInjection200 mg/2 mL, 150 mg/mLSDL
CimetidineTablet200 mgSDL
CiprofloxacinTablet250 mg, 500 mgSDL
CiprofloxacinEye/ear drops0.3%SDL
Ciprofloxacin Infusion2 mg/mLSDL
CisplatinConcentrate for infusion50 mg/50 mLSDL
Citric Acid Monohydrate & Potassium Citrate Oral solutionCitric Acid Monohydrate 0.25 g/5 mL + Potassium Citrate 1.5 g/5 mLSDL
ClarithromycinModified-release tablet500 mgSDL
ClarithromycinTablet250 mg, 500 mgSDL
Clarithromycin Injection500 mgSDL
Clarithromycin Oral suspension125 mg/5 mLSDL
Clidinium & ChlordiazepoxideTabletClidinium Bromide 2.5 mg + Chlordiazepoxide 5 mgSDL
Clindamycin Capsule150 mgSDL
Clindamycin Injection150 mg/mLSDL
ClomipheneTablet50 mgSDL
ClomipramineTablet25 mgSDL
ClonazepamTablet0.5 mg, 2 mgSDL
ClopidogrelTablet75 mgSDL
ClotrimazoleCream1%SDL
ClotrimazoleLotion1%SDL
ClotrimazolePowder1%SDL
ClotrimazoleVaginal tablet100 mgSDL
CloxacillinCapsule250 mgSDL
CloxacillinInjection250 mg, 500 mgSDL
CloxacillinSyrup125 mg/5 mLSDL
ClozapineTablet25 mg, 100 mgSDL
Coal TarCream5%, 10%, 15%SDL
Coal TarLotion20%SDL
Coal TarShampoo25%SDL
Coal Tar & Salicylic AcidOintmentCoal Tar 5% + Salicylic acid 2%, Coal Tar 10% + Salicylic acid 2%, Coal Tar 15% + Salicylic acid 2%SDL
CocaineSolution 10%SDL
Cocois CompoundOintmentCoal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2%SDL
Codeine & PromethazineSyrupCodeine Phosphate 18 mg/10 mL + Promethazine 7.2 mg/10 mLSDL
Codeine PhosphateTablet30 mgSDL
ColchicineTablet500 mcgSDL
ColecalciferolTablet1,000 unitsSDL
ColestyraminePowder for oral suspension4 gSDL
Compound DiphenhydramineSyrup5 mg/5 mL, 10 mg/5 mLSDL
Compound Polyethylene Glycol (Fortrans)Oral powder-SDL
Compound Sodium Lactate Infusion-SDL
Conjugated OestrogensTablet0.3 mg, 0.625 mgSDL
Conjugated OestrogensVaginal cream0.625 mg/gSDL
CyanocobalaminInjection1 mg/mLSDL
CyclophosphamideInfusion200 mg, 1 gSDL
CyclophosphamideTablet50 mgSDL
CyproheptadineTablet4 mgSDL
CytarabineInjection20 mg/mL, 100 mg/mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
DacarbazineInjection200 mgSDL
DactinomycinInfusion500 mcgSDL
Dantrolene Sodium Capsule25 mg, 100 mgSDL
DapagliflozinTablet5 mg, 10 mgMAF1) Treatment of type 2 diabetes mellitus, as a dual therapy
o In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated, not tolerated, or the person is at significant risk of hypoglycaemia;
o In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;
2) Treatment of type 2 diabetes mellitus as a triple therapy
o In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy
3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin
DapsoneTablet100 mgSDL
DaunorubicinInjection20 mgSDL
Deferiprone Oral solution100 mg/mLSDL
Deferiprone Tablet500 mgSDL
Deferoxamine Mesilate Injection500 mgSDL
DenosumabPrefilled syringe60 mg/mLMAFTreatment of post-menopausal women with osteoporosis (T-score ≤ -2.5) at high risk of fracture and eGFR > 30 mL/min and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Dequalinium Chloride Lozenge0.25 mgSDL
Desmopressin Acetate Nasal drops0.1 mg/mLSDL
Desmopressin Acetate Nasal spray10 mcg/doseSDL
Desmopressin Acetate Tablet0.1 mg, 0.2 mgSDL
DexamethasoneTablet500 mcg, 4 mgSDL
Dexamethasone Phosphate Injection4 mg/mLSDL
Dexmedetomidine Concentrate for infusion200 mcg/2 mLSDL
Dextromethorphan Hydrobromide Syrup15 mg/5 mLSDL
Dextromethorphan Hydrobromide Tablet15 mgSDL
Dextrose & Potassium ChlorideInfusionDextrose 5% + Potassium Chloride 0.15%SDL
Dextrose & Sodium ChlorideInfusionDextrose 2.5% + Sodium Chloride 0.45%, Dextrose 3.75% + Sodium Chloride 0.23%, Dextrose 5% + Sodium Chloride 0.2%, Dextrose 5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.9% SDL
Dextrose Monohydrate Infusion5%, 10%, 20%, 50%SDL
Dextrose, Potassium Chloride & Sodium ChlorideInfusionDextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.33%, Dextrose 5% + Potassium Chloride 0.22% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.30% + Sodium Chloride 0.45%SDL
DiazepamEnema5 mg/2.5 mLSDL
DiazepamInjection5 mg/mLSDL
DiazepamTablet2 mg, 5 mg, 10 mgSDL
Dibasic Sodium Phosphate & Monobasic Sodium PhosphateEnemaDibasic Sodium Phosphate 7 g/118 mL + Monobasic Sodium Phosphate 19 g/118 mLSDL
Diclofenac SodiumEnteric-coated tablet25 mg, 50 mgSDL
Diclofenac SodiumInjection25 mg/mLSDL
Diclofenac SodiumRectal suppository12.5 mg, 25 mg, 50 mgSDL
Diclofenac SodiumGel1%SDL
Diethylcarbamazine Citrate Tablet50 mgSDL
DigoxinInjection100 mcg/mL, 250 mcg/mLSDL
DigoxinOral solution50 mcg/mLSDL
DigoxinTablet62.5 mcg, 250 mcgSDL
Digoxin-specific Antibody Fragments Injection40 mgSDL
Diltiazem Hydrochloride Injection10 mg, 50 mgSDL
Diltiazem Hydrochloride Sustained-release capsule90 mg, 100 mg, 200 mgSDL
Diltiazem Hydrochloride Tablet30 mg, 60 mgSDL
DimercaprolInjection50 mg/mLSDL
Diosmin & HesperidinTabletDiosmin 450 mg + Hesperidin 50 mgSDL
Diphenoxylate & Atropine SulfateTabletDiphenoxylate Hydrochloride 2.5 mg + Atropine Sulfate 25 mcgSDL
Diphtheria & Tetanus VaccineInjectionDiphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mLSDL
Diphtheria AntitoxinInjection10,000 unitsSDL
Diphtheria, Tetanus & Pertussis VaccineInjectionDiphtheria Toxoid Vaccine minimum 30 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 40 international units/0.5 mL + Pertussis Toxoid Vaccine 25 microgram/0.5 mL + Filamentous Haemagglutinin 25 microgram/0.5 mL + Pertactin 8 microgram/0.5 mLSDL
DipyridamoleTablet25 mg, 75 mgSDL
Disodium EdetateEye drops0.38%, 3%SDL
DithranolOintment1%, 2%SDL
DobutamineConcentrate for infusion250 mg/5 mL, 250 mg/20 mLSDL
DocetaxelInfusion20 mg, 80 mg, 160 mgMAF1) For the treatment of patients with locally advanced or metastatic breast cancer.
2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer.
3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer.
4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer.
Donepezil HydrochlorideOral disintegrating tablet5 mg, 10 mgMAFFor patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Donepezil HydrochlorideTablet5 mg, 10 mgSDL
Dopamine Hydrochloride Concentrate for infusion200 mg/5 mLSDL
Dothiepin Hydrochloride Tablet75 mgSDL
Dothiepin Hydrochloride Capsule25 mgSDL
Doxorubicin Hydrochloride Injection10 mg, 50 mgSDL
DoxycyclineCapsule100 mgSDL
DroperidolInjection2.5 mg/mLSDL
DydrogesteroneTablet10 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Emulsifying OintmentOintment-SDL
Enalapril Maleate Tablet5 mg, 10 mg, 20 mgSDL
Enoxaparin Sodium Injection10,000 anti-Xa international units/mLSDL
EntacaponeTablet200 mgSDL
Entecavir Oral solution0.05 mg/mLMAFTreatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Entecavir Tablet0.5 mg, 1 mgMAFTreatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Ephedrine Sulfate Injection30 mg/mLSDL
Epoetin AlfaInjection 2,000 international units/0.5 mL, 4,000 international units/0.4 mLSDL
Epoetin BetaInjection2,000 international units/0.3 mL, 4,000 international units/0.3 mLSDL
Ergometrine Maleate Injection500 mcg/mLSDL
Ergotamine & CaffeineTabletCaffeine 100 mg + Ergotamine Tartrate 1 mgSDL
Erythromycin (as Ethyl Succinate)Tablet400 mgSDL
Erythromycin (as Ethyl Succinate) Oral suspension200 mg/5 mLSDL
Erythromycin (as Lactobionate) Infusion500 mg, 1 gSDL
Erythromycin StearateEnteric-coated tablet250 mg SDL
EstradiolVaginal tablet10 mcg, 25 mcgSDL
EtanerceptPrefilled syringe25 mg/0.5 mL, 50 mg/mLMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of juvenile idiopathic arthritis
6) Treatment of adult patients with chronic plaque psoriasis
MAF will no longer be applicable for etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis after 30 September 2018.
EtanerceptInjection25 mg/mLMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of juvenile idiopathic arthritis
6) Treatment of adult patients with chronic plaque psoriasis
MAF will no longer be applicable for etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis after 30 September 2018.
Ethambutol Hydrochloride Tablet100 mg, 400 mgSDL
EthanolSolutionEthanol 95%SDL
EthionamideTablet125 mgSDL
Ethyl ChlorideTopical spray88 g/100 mLSDL
EtoposideCapsule50 mg, 100 mgSDL
EtoposideConcentrate for infusion20 mg/mLSDL
EverolimusTablet0.25 mg, 0.75 mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
FamotidineTablet20 mgSDL
FenofibrateCapsule100 mg, 300 mgSDL
FentanylInjection50 mcg/mLSDL
FentanylTransdermal patch12 mcg/hr, 25 mcg/hr, 50 mcg/hrSDL
Ferrous FumarateTablet200 mgSDL
Ferrous GluconateTablet300 mgSDL
Ferrous Gluconate, Multivitamins & Minerals CapsuleFerrous Gluconate 250 mg + Vit B12 7.5 mcg + Vit C 50 mg + Folic Acid 1 mg + Sorbitol 25 mg + Copper Sulfate 200 mcg + Manganese Sulfate 200 mcgSDL
Ferrous Sulphate & Vitamin B1 & Riboflavin & NicotinamideTabletFerrous Sulphate 200 mg + Vitamin B1 3 mg + Riboflavin 1.5 mg + Nicotinamide 10 mgSDL
FilgrastimInjection30 million units/0.5 mL (300 mcg/0.5 mL), 30 million units/mL (300 mcg/mL)SDL
Finasteride Tablet5 mgSDL
FluconazoleCapsule50 mg, 100 mg, 150 mgSDL
FluconazoleInfusion100 mg/50 mLSDL
Fludrocortisone Acetate Tablet0.1 mgSDL
FlumazenilInjection0.1 mg/mLSDL
Fluocinolone AcetonideCream0.003125%, 0.00625%, 0.0125%, 0.025%SDL
Fluorescein SodiumInjection10%SDL
Fluorescein SodiumSingle-use eye drops2%SDL
FluorouracilInjection50 mg/mLSDL
FluoxetineCapsule10 mg, 20 mgSDL
Flupenthixol DecanoateInjection20 mg/mL, 40 mg/2 mLSDL
Fluphenazine DecanoateInjection25 mg/mLSDL
Fluticasone PropionateInhaler50 mcg/dose, 125 mcg/dose, 250 mcg/doseSDL
Fluvoxamine MaleateTablet50 mgSDL
Folic AcidTablet5 mgSDL
Folinic AcidInjection10 mg/mLSDL
Formoterol & BudesonidePowder inhalerFormoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose, Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose, Formoterol Fumarate Dihydrate 9 mcg/dose + Budesonide 320 mcg/doseSDL
Furosemide Injection10 mg/mLSDL
Furosemide Tablet40 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
GabapentinCapsule100 mg, 300 mg, 400 mgSDL
GanciclovirInfusion500 mgSDL
Gelatin Succinylated & Sodium Chloride InfusionGelatin Succinylated 4 g/100 mL + Sodium Chloride 0.701 g/100 mLSDL
GemcitabineInfusion200 mg, 1000 mg, 2000 mgSDL
GemfibrozilCapsule300 mgSDL
GentamicinInjection40 mg/mLSDL
GentamicinEye drops0.3%SDL
Gentian VioletPaint0.5%SDL
GlibenclamideTablet5 mgSDL
GliclazideTablet80 mgSDL
GlipizideTablet5 mgSDL
GlucagonInjection1 mgSDL
GlycerolRectal suppository1 g, 1.5 g, 2 gSDL
Glycerol, Methyl Salicylate, Sodium Salicylate & Thymol CompoundMouthwashGlycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05%SDL
Glyceryl TrinitrateOral spray0.4 mg/doseSDL
Glyceryl TrinitratePatch5 mg, 10 mgSDL
Glyceryl TrinitrateSublingual tablet0.5 mgSDL
GlycineIrrigation solution1.5%SDL
GolimumabPrefilled syringe50 mg/0.5 mLMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with ulcerative colitis
GolimumabPrefilled pen50 mg/0.5 mLMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with ulcerative colitis
Goserelin Subcutaneous injectable implant3.6 mg, 10.8 mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
GriseofulvinTablet125 mg, 500 mgSDL
Guaifenesin Syrup100 mg/5 mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Haemodialysis Concentrate 35X (Acetate Salt)SolutionThe diluted solution contains: Na+ 140.0 mmol/L, K+ 2.60 mmol/L, Ca2+ 1.38 mmol/L, Mg2+ 0.62 mmol/L, Cl- 102 mmol/L, HCO3- 45 mmol/LSDL
Haemodialysis Concentrate 35X (Bicarbonate)Solution (comprised 2 separate 10 L canisters: acidic & basic)Acidic concentrate: KCl 5.5 g/L, NaCl 161.0 g/L, CaCl2.2H2O 9.7 g/L, MgCl2.6H2O 3.7 g/L, CH3COOH (glacial) 8.8 g/L; Basic concentrate: NaCl 30.5 g/L, HCO3- 66.0 g/L; Final diluted solution contains: Na+ 140 mmol/L, K+ 2.0 mmol/L, Ca2+ 1.8 mmol/L, Mg2+ 0.5 mmol/L, Cl- 107.2 mmol/L, CH3COO- 4.0 mmol/L, HCO3- 35.0 mmol/LSDL
HaloperidolInjection5 mg/mLSDL
HaloperidolOral solution2 mg/mLSDL
HaloperidolTablet0.5 mg, 1.5 mg, 5 mgSDL
Heparin Sodium Injection1,000 units/mL, 5,000 units/mL, 25,000 units/5 mLSDL
Heparinised SalineInjection (in sodium chloride 0.9%, preservative-free)50 international units/5 mLSDL
Hepatitis B ImmunoglobulinInjection≥ 200 international units/mL (adults), ≥100 international units/mL (children)SDL
Homatropine Hydrobromide Eye drops2%SDL
Hydralazine HydrochlorideTablet10 mg, 25 mg, 50 mgSDL
Hydralazine Hydrochloride Injection20 mg/mLSDL
HydrochlorothiazideTablet25 mgSDL
Hydrocolloid (carboxymethylcellulose-containing)Dressing-SDL
Hydrocolloid (carboxymethylcellulose-containing)Gel-SDL
HydrocortisoneCream0.5%, 1%SDL
HydrocortisoneLotion0.5%SDL
HydrocortisoneOintment1%SDL
HydrocortisoneTablet10 mgSDL
Hydrocortisone (as Sodium Succinate)Injection100 mgSDL
Hydrocortisone AcetateRectal enema100 mg/100 mL, 200 mg/100 mLSDL
Hydrocortisone Acetate & ClioquinolCreamHydrocortisone Acetate 1% + Clioquinol 3%SDL
Hydrogen PeroxideMouthwash3%SDL
Hydrogen PeroxideTopical solution3%SDL
Hydroxychloroquine SulphateTablet200 mgSDL
Hydroxychloroquine Sulphate Tablet200 mgSDL
Hydroxyprogesterone CaporateInjection250 mg/mLSDL
HydroxyureaCapsule500 mgSDL
Hydroxyzine HydrochlorideTablet10 mg, 25 mgSDL
Hydroxyzine Hydrochloride Syrup10 mg/5 mLSDL
Hyoscine ButylbromideInjection20 mg/mLSDL
Hyoscine ButylbromideTablet10 mgSDL
Hyoscine Hydrobromide TrihydrateInjection400 mcg/mLSDL
HypromelloseEye drops0.3%SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
IbuprofenOral liquid100 mg/5 mLSDL
IbuprofenTablet200 mgSDL
IfosfamideInfusion1 gSDL
Imipenem & Cilastatin InfusionImipenem 500 mg + Cilastatin 500 mgSDL
Imipramine Hydrochloride Tablet10 mg, 25 mgSDL
IndometacinCapsule25 mgSDL
Infliximab (Remicade)Injection100 mgMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with Crohn's disease
5) Treatment of children (6 to 17 years) with Crohn's disease
6) Treatment of adult patients with ulcerative colitis
7) Treatment of children (6 to 17 years) with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
MAF will no longer be applicable for Remicade for all indications after 31 December 2018.
Infliximab (Remsima) Infusion100 mgMAFChecklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with Crohn's disease
5) Treatment of children (6 to 17 years) with Crohn's disease
6) Treatment of adult patients with ulcerative colitis
7) Treatment of children (6 to 17 years) with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
Insulin AspartInjection, penfill100 international units/mLMAFType 1 & 2 diabetes mellitus
Insulin AspartInjection, prefilled pen100 international units/mLMAFType 1 & 2 diabetes mellitus
Insulin Aspart & Insulin Aspart ProtamineInjection, prefilled penInsulin Aspart 30% + Insulin Aspart Protamine 70%MAFType 1 & 2 diabetes mellitus
Insulin DetemirInjection, prefilled pen100 international units/mLSDL
Insulin Glargine (Basaglar)Injection, cartridge100 international units/mLSDL
Insulin Glargine (Lantus)Injection100 international units/mLSDL
Insulin Glargine (Lantus)Injection, penfill100 international units/mLSDL
Insulin Glargine (Lantus)Injection, prefilled pen100 international units/mLSDL
Insulin GlulisineInjection, prefilled pen100 international units/mLSDL
Insulin Isophane (Human)Injection100 international units/mLSDL
Insulin Isophane (Human)Injection, penfill100 international units/mLSDL
Insulin LisproInjection100 international units/mLMAFType 1 & 2 diabetes mellitus
Insulin LisproInjection, penfill100 international units/mLMAFType 1 & 2 diabetes mellitus
Insulin LisproInjection, prefilled pen100 international units/mLMAFType 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro ProtamineInjection, penfillInsulin Lispro 25% + Insulin Lispro Protamine 75% SDL
Insulin Lispro & Insulin Lispro ProtamineInjection, prefilled penInsulin Lispro 25% + Insulin Lispro Protamine 75% MAFType 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro ProtamineInjection, prefilled penInsulin Lispro 50% + Insulin Lispro Protamine 50% MAFType 1 & 2 diabetes mellitus
Insulin Soluble & Insulin Isophane (Human)InjectionInsulin Soluble 30% + Insulin Isophane 70%SDL
Insulin Soluble & Insulin Isophane (Human)Injection, penfillInsulin Soluble 30% + Insulin Isophane 70%SDL
Insulin Soluble (Human)Injection100 international units/mLSDL
Insulin Soluble (Human)Injection, penfill100 international units/mLSDL
Interferon Alfa-2aInjection3 million international units/0.5 mL, 6 million international units/0.5 mLSDL
Intraperitoneal DialysisSolutionDextrose 1.5%, 2.5% or 4.25% with Ca2+ 1.25 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 95 mmol/L, Lactate 40 mmol/L; Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 2.57 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 96 mmol/L, Lactate 40 mmol/LSDL
IodineTopical solution0.5%, 1.0%, 2.5%SDL
Iodine Aqueous Oral solutionIodine 5% + Potassium iodide 10% SDL
Ipratropium Bromide Inhaler20 mcg/doseSDL
Ipratropium Bromide Nebulisation solution0.025%SDL
Irinotecan Hydrochloride TrihydrateInfusion20 mg/mLSDL
Iron (as Polymaltose) Oral drops50 mg/mLSDL
Iron (as Sucrose) Injection100 mg/5 mLSDL
IsoniazidTablet100 mg, 300 mgSDL
Isoprenaline HydrochlorideInjection0.2 mg/mL, 1 mg/mLSDL
Isoprenaline SulfateInjection0.2 mg/mL, 1 mg/mLSDL
Isosorbide DinitrateTablet10 mgSDL
Isosorbide MononitrateSustained-release tablet60 mgSDL
ItraconazoleCapsule100 mgSDL
ItraconazoleOral solution10 mg/mLMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
IvabradineTablet5 mg, 7.5 mgMAFTreatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
KanamycinInjection1 gSDL
Kaolin, Magnesium Carbonate (light) & Sodium Bicarbonate Oral suspensionKaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5%SDL
KetoprofenEnteric-coated tablet100 mgSDL
KetoprofenSlow-release tablet200 mgSDL
KetoprofenGel2.5%SDL
"
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
LactuloseSyrup3.3 g/5 mL, 3.35 g/5 mLSDL
LamivudineTablet 100 mgSDL
LamotrigineDispersible tablet5 mgSDL
LamotrigineTablet50 mg, 100 mgSDL
Land Snakes Antivenom Concentrate for infusion-SDL
L-AsparaginaseInjection10,000 international unitsSDL
LatanoprostEye drops0.005%SDL
Leflunomide Tablet10 mg, 20 mg, 100 mgMAF1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate
2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
LetrozoleTablet2.5 mgSDL
Leuprorelin Acetate Injection3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg, 5 mg/mLMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Levetiracetam Concentrate for infusion100 mg/mLMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam Oral solution100 mg/mLMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam Tablet250 mg, 500 mg, 1 gMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levodopa & BenserazideCapsuleLevodopa 100 mg + Benserazide 25 mgSDL
Levodopa & BenserazideTabletLevodopa 200 mg + Benserazide 50 mgSDL
Levodopa & BenserazideControlled-release capsuleLevodopa 100 mg + Benserazide 25 mgSDL
Levodopa & CarbidopaTabletLevodopa 100 mg + Carbidopa 25 mg, Levodopa 250 mg + Carbidopa 25 mgSDL
Levodopa & Carbidopa Sustained-release tabletLevodopa 200 mg + Carbidopa 50 mg SDL
Levodopa, Carbidopa & EntacaponeTabletLevodopa 50 mg + Carbidopa 12.5 mg + Entacapone 200 mg, Levodopa 100 mg + Carbidopa 25 mg + Entacapone 200 mg, Levodopa 150 mg + Carbidopa 37.5 mg + Entacapone 200 mg, Levodopa 200 mg + Carbidopa 50 mg + Entacapone 200 mgSDL
Levonorgestrel & EthinylestradiolTabletLevonorgestrel 0.15 mg + Ethinylestradiol 0.03 mgSDL
Levothyroxine Sodium Tablet25 mcg, 50 mcg, 75 mcg, 100 mcgSDL
LidocaineOintment5%SDL
LidocaineTopical solution4%SDL
LidocaineTopical spray10%SDL
Lidocaine & AdrenalineInjectionLidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/mL)SDL
Lidocaine & PrilocaineCreamLidocaine 2.5% + Prilocaine 2.5%SDL
Lidocaine Hydrochloride Gel2%SDL
Lidocaine Hydrochloride Injection1%, 10% SDL
Lidocaine Hydrochloride Oral solution (viscous)2%SDL
Lidocaine Hydrochloride Injection (preservative-free)1%, 1.5%, 2%, 10%SDL
LinagliptinTablet5 mgMAFFor patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
Liothyronine Sodium Tablet20 mcgSDL
Liquid ParaffinOral emulsion2.5 mL/5 mLSDL
Liquid ParaffinLiquid-SDL
LisinoprilTablet5 mg, 10 mg, 20 mgSDL
Lithium CarbonateControlled-release tablet400 mgSDL
LomustineCapsule40 mgSDL
LoratadineSyrup5 mg/5 mLSDL
LoratadineTablet10 mgSDL
LorazepamTablet0.5 mg, 1 mgSDL
Losartan Potassium Tablet50 mg, 100 mgSDL
LovastatinTablet20 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Magnesium Carbonate & Sodium BicarbonateOral suspensionMagnesium Carbonate 150 mg/5 mL + Sodium Bicarbonate 250 mg/5 mL + Aromatic Cardamon Tincture 0.15 mL/5 mLSDL
Magnesium Chloride Hexahydrate, Potassium Chloride & Procaine HydrochlorideConcentrate for infusionMagnesium Chloride Hexahydrate 162.5 mg/mL (0.8 mmol/mL) + Potassium Chloride 59.5 mg/mL (0.8 mmol/mL) + Procaine Hydrochloride 13.64 mg/mL (0.05 mmol/mL)SDL
Magnesium SulfateInjection49.3%SDL
Magnesium SulfateInjection49.3% (2 mmol Mg2+/mL)SDL
Magnesium TrisilicateOral suspensionMagnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5% Oral SuspensionSDL
MalathionLotion0.5%SDL
MannitolInfusion20%SDL
Measles, Mumps, Rubella VaccineInjectionMeasles Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mL + Mumps Virus Vaccine (live-attenuated) minimum 12,500 CCID50/0.5 mL + Rubella Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mLSDL
Mebeverine Hydrochloride Tablet135 mgSDL
Medroxyprogesterone AcetateInjection50 mg/mLSDL
Medroxyprogesterone AcetateTablet5 mg, 10 mgSDL
Mefenamic AcidCapsule250 mgSDL
MefloquineTablet250 mgSDL
MelphalanInjection50 mgSDL
MelphalanTablet2 mgSDL
MercaptopurineTablet50 mgSDL
Meropenem Injection500 mg, 1 gSDL
Mesalazine Enema2 g/30 mLSDL
Mesalazine Enteric-coated tablet250 mg, 400 mg, 500 mg, 800 mgSDL
Mesalazine Slow-release tablet500 mgSDL
Mesalazine Suppository250 mg, 500 mg, 1 gSDL
MesnaInjection100 mg/mLSDL
MesnaTablet400 mg, 600 mgSDL
Metformin HydrochlorideTablet250 mg, 500 mg, 850 mgSDL
MethadoneTablet5 mgSDL
MethionineTablet250 mg, 2.5 gSDL
MethotrexateInjection50 mg/2 mL, 1 g/10 mLSDL
MethotrexateTablet2.5 mgSDL
MethotrexateInjection (preservative-free)50 mg/2 mLSDL
Methotrexate Tablet2.5 mgSDL
MethoxsalenLotion0.01%, 0.05%, 0.1%, 0.75%SDL
MethoxsalenCapsule10 mgSDL
MethoxsalenTablet 10 mgSDL
Methyl SalicylateCream10%-20%SDL
Methyl SalicylateSolution25%SDL
Methylated SpiritTopical solution70%SDL
MethyldopaTablet125 mg, 250 mgSDL
Methylphenidate HydrochlorideExtended-release tablet18 mg, 27 mg, 36 mg, 54 mgMAFAttention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate HydrochlorideModified-release capsule20 mgMAFAttention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride Sustained-release tablet20 mgMAFAttention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride Tablet10 mgSDL
Methylprednisolone (as Sodium Succinate) Injection62.5 mg/mLSDL
Metoclopramide HydrochlorideInjection5mg/mLSDL
Metoclopramide Hydrochloride Tablet10 mgSDL
MetronidazoleInfusion5 mg/mLSDL
MetronidazoleTablet200 mgSDL
MiconazoleOral gel2%SDL
Miconazole Nitrate Cream2%SDL
MidazolamInjection5 mg/mL, 5 mg/5 mLSDL
Midodrine HydrochlorideTablet5 mgSDL
MirtazapineOral disintegrating tablet15 mg, 30 mgSDL
MirtazapineTablet30 mgSDL
MitomycinInjection2 mg, 10 mgSDL
Mitoxantrone Injection2 mg/mLSDL
MoclobemideTablet150 mgSDL
Mometasone FuroateNasal spray0.05%MAFFor treatment of allergic rhinitis in
1) Children from 2–6 years old
2) Children above 6 years to 12 years who are unable to use other alternative intra-nasal steroidal preparation
Morphine Sulfate Controlled-release tablet10 mg, 30 mgSDL
Morphine Sulfate Injection10 mg/mLSDL
Morphine Sulfate Oral solution10 mg/5 mLSDL
Morphine Sulfate Syrup1 mg/mLSDL
Multivitamin for PaediatricsOral solutionAscorbic acid 35 mg/mL + Riboflavine 0.6 mg/mL + Nicotinamide 8 mg/mL + Thiamine 0.5 mg/mL + Pyridoxine 0.4 mg/mL + Calciferol 400 international units/mL + Cyanocobalamin 2.0 mcg/mL + Vitamin A 1,500 international units/mLSDL
MydricaineOphthalmic solution Atropine Sulfate 0.34% + Cocaine HCl 2% + Adrenaline 0.034% + Sodium Chloride 0.26%SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Nalidixic AcidTablet500 mgSDL
Naloxone HydrochlorideInjection0.4 mg/mL, 0.02 mg/mLSDL
Nandrolone DecanoateInjection25 mg/mLSDL
Naphazoline Hydrochloride & Pheniramine MaleateEye dropsNaphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3%SDL
Neomycin SulfateTablet500 mgSDL
Neomycin, Polymyxin B & DexamethasoneEar dropsNeomycin Sulfate 6,500 international units/mL + Polymyxin B Sulfate 10,000 international units/mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/mLSDL
Neostigmine MetilsulfateInjection0.5 mg/mL, 2.5 mg/mLSDL
Nicotinic AcidTablet50 mgSDL
NifedipineExtended-release tablet30 mg, 60 mgSDL
NifedipineTablet5 mg, 10 mgSDL
Nifedipine Capsule5 mg, 10 mgSDL
NitrazepamTablet5 mgSDL
NitrofurantoinTablet50 mgSDL
NorepinephrineConcentrate for infusion4 mg/4 mLSDL
NorethisteroneTablet5 mgSDL
NortriptylineCapsule10 mg, 25 mgSDL
NystatinOral suspension100,000 units/mLSDL
NystatinVaginal tablet100,000 unitsSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Olanzapine Oral disintegrating tablet5 mg, 10 mgSDL
Olanzapine Tablet5 mg, 10 mgSDL
Olive OilEar drops-SDL
OmeprazoleCapsule20 mgSDL
OndansetronInjection2 mg/mLSDL
OndansetronTablet8 mgSDL
Oral Rehydration SaltsEffervescent tablet-SDL
Oral Rehydration SaltsOral powder for reconstitution-SDL
OxaliplatinConcentrate for infusion50 mg/10 mL, 100 mg/50 mLSDL
OxaliplatinInfusion50 mg, 100 mgSDL
Oxybutynin Chloride Tablet5 mgSDL
Oxymetazoline Hydrochloride Nasal drops0.01%, 0.025%, 0.05%SDL
Oxymetazoline Hydrochloride Nasal spray0.025%, 0.05%SDL
OxytocinInjection10 international units/mLSDL
Oxytocin & Ergometrine MaleateInjectionOxytocin 5 international units/mL + Ergometrine Maleate 0.5 mg/mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
PaclitaxelConcentrate for infusion6 mg/mLSDL
Pamidronate DisodiumInfusion30 mg, 90 mgMAF1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma
2) Treatment of hypercalcaemia of malignancy
Pancuronium Bromide Concentrate for infusion2 mg/mLSDL
ParacetamolInfusion500 mg/50 mL, 1,000 mg/100 mLSDL
ParacetamolOral suspension120 mg/5 mLSDL
ParacetamolRectal suppository125 mg, 250 mg, 325 mg, 650 mgSDL
ParacetamolTablet120 mg, 500 mgSDL
Paracetamol & Orphenadrine CitrateTabletParacetamol 450 mg + Orphenadrine Citrate 35 mgSDL
ParaffinLiquid-SDL
Paraffin Soft & Paraffin LiquidEmulsionSoft Paraffin 50% + Liquid Paraffin 50%SDL
Peginterferon Alfa-2a Injection135 mcg/0.5 mL, 180 mcg/0.5 mLMAF1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.
Peginterferon Alfa-2b Injection50 mcg/0.5 mL, 80 mcg/0.5 mL, 100 mcg/0.5 mL, 120 mcg/0.5 mL, 150 mcg/0.5 mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
PenicillamineCapsule250 mgSDL
Pethidine Hydrochloride Injection50 mg/mLSDL
Phenazopyridine Hydrochloride Tablet100 mgSDL
Phenobarbital Sodium Injection20 mg/0.5 mLSDL
PhenobarbitoneTablet10 mg, 30 mg, 60 mgSDL
Phenol (in almond oil)Injection5%SDL
PhenoxymethylpenicillinTablet250 mgSDL
Phenylephrine HydrochlorideSingle-use eye drops2.5%, 10%SDL
Phenylephrine Hydrochloride Eye drops2.5%, 10% SDL
PhenytoinOral suspension125 mg/5 mLSDL
Phenytoin SodiumInjection50 mg/mLSDL
Phenytoin Sodium Capsule30 mg, 100 mgSDL
Phosphate BufferPowder-SDL
Physostigmine SalicylateInjection1 mg/mLSDL
PhytomenadioneInjection10 mg/mLSDL
Pilocarpine Hydrochloride Eye drops1%, 2%, 4%SDL
Pilocarpine Nitrate Single-use eye drops2%SDL
Piperacillin & Tazobactam InjectionPiperacillin 4 g + Tazobactam 0.5 gSDL
Pipotiazine PalmitateInjection50 mg/mLSDL
PiroxicamCapsule10 mg, 20 mgSDL
Podophyllum ResinPaint0.25%, 0.5%SDL
Poliomyelitis Vaccine (live-attenuated) Oral suspensionPoliovirus Vaccine (type 1 live-attenuated) minimum 1,000,000 TCID50/0.5 mL + Poliovirus Vaccine (type 2 live-attenuated) minimum 100,000 TCID50/0.5 mL + Poliovirus Vaccine (type 3 live-attenuated) minimum 300,000 TCID50/0.5 mLSDL
PosaconazoleDelayed-release tablet100 mgMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
PosaconazoleOral suspension40 mg/mLMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Potassium ChlorideSlow-release tablet600 mgSDL
Potassium ChlorideOral solution500 mg/5 mL SDL
Potassium ChlorideConcentrate for infusion7.45%SDL
Potassium ChlorideInfusion0.1 mmol/mL, 0.2 mmol/mL, 0.4 mmol/mLSDL
Potassium Chloride & Sodium ChlorideInfusionPotassium Chloride 0.15% + Sodium Chloride 0.9%SDL
Potassium CitrateOral solution500 mg/5 mLSDL
Potassium PermanganateCrystals100%SDL
Potassium PermanganateTopical solution0.1%SDL
Potassium Phosphate Monobasic Concentrate for infusion1 mmol/mL (0.1361 g/mL)SDL
Povidone-IodineTopical solution10%SDL
Pralidoxime Chloride Injection500 mg/20 mLSDL
Pramipexole Dihydrochloride MonohydrateTablet0.125 mg, 1 mgSDL
Pravastatin SodiumTablet20 mgSDL
PrazosinTablet1 mg, 5 mgSDL
PrednisoloneSyrup10 mg/5 mLSDL
PrednisoloneTablet1 mg, 5 mg, 20 mgSDL
PrimaquineTablet7.5 mg, 15 mgSDL
ProbenecidTablet500 mgSDL
Procainamide HydrochlorideInjection100 mg/mLSDL
Procaine Hydrochloride Lotion (in spirit 70%)2%SDL
ProcarbazineCapsule50 mgSDL
Prochlorperazine Maleate Tablet5 mgSDL
Prochlorperazine MesilateInjection12.5 mg/mLSDL
ProgesteroneInjection50 mg/mLSDL
Promethazine Hydrochloride Syrup5 mg/5mLSDL
Promethazine Hydrochloride Injection25 mg/mLSDL
Promethazine Hydrochloride Syrup5 mg/5 mLSDL
Promethazine TheoclateTablet25 mgSDL
Propantheline BromideTablet15 mgSDL
Proparacaine Hydrochloride Eye drops0.5%SDL
PropofolInjection10 mg/mLSDL
Propranolol HydrochlorideInjection1 mg/mLSDL
Propranolol Hydrochloride Tablet10 mg, 40 mg, 80 mgSDL
Propylene GlycolSolution40%SDL
Propylene Glycol In Aqueous CreamCream20%, 40% SDL
PropylthiouracilTablet50 mgSDL
Protamine SulfateInjection1% (10 mg/mL)SDL
PyrazinamideTablet500 mgSDL
Pyridostigmine BromideTablet10 mg, 60 mgSDL
Pyridoxine HydrochlorideTablet10 mg, 50 mgSDL
PyrimethamineTablet25 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Quetiapine Tablet25 mg, 100 mg, 200 mgSDL
Quinine Sulfate Tablet300 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Rabies Virus Vaccine (Inactivated) InjectionMinimum 2.5 international unitsSDL
RifampicinCapsule150 mg, 300 mgSDL
Risedronate Sodium Tablet5 mg, 35 mgMAF1) For patients with osteoporosis (T-score ≤ -2.5)
2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
RisperidoneOral solution1 mg/mLSDL
RisperidoneTablet0.5 mg, 1 mg, 2 mgSDL
RituximabConcentrate for infusion100 mg/10 mL, 500 mg/50 mLMAF1) Treatment of patients with CD20 positive diffuse large B cell lymphoma
2) Treatment of patients with CD20 positive follicular non-Hodgkin's lymphoma
RivaroxabanTablet15 mg, 20 mgMAF1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA2DS2-VASc score of 1 or more for men, and 2 or more for women
*This excludes patients with rheumatic mitral stenosis or prosthetic heart valves
2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
RivastigmineTransdermal patch4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hrMAFChecklist to be completed
1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms
2) Rivastigmine patch formulation (4.6 mg/24 hr, 9.5 mg/24 hr and 13.3 mg/24 hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms
RopiniroleTablet0.25 mg, 1 mg, 2 mgSDL
Rubella Virus Vaccine (live-attenuated)InjectionMinimum 1,000 TCID 50/0.5 mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
SalbutamolInhaler100 mcg/doseSDL
SalbutamolNebulisation solution0.5%SDL
SalbutamolConcentrate for infusion5 mg/5 mLSDL
SalbutamolOral liquid2 mg/5 mLSDL
SalbutamolTablet2 mgSDL
Salicylic AcidCream2%, 20%SDL
Salicylic AcidOintment1%, 2%, 5%, 10%, 20%, 40%SDL
Salicylic Acid & Lactic Acid Topical solutionSalicylic Acid 16.7% + Lactic Acid 16.7% Collodion, Salicylic Acid 17% + Lactic Acid 17% CollodionSDL
Salmeterol & Fluticasone PropionateInhalerSalmeterol 25 mcg/dose + Fluticasone Propionate 50 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 125 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 250 mcg/doseSDL
Salmeterol & Fluticasone PropionatePowder inhalerSalmeterol 50 mcg/dose + Fluticasone Propionate 100 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 250 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 500 mcg/doseSDL
Sea Snake Venom AntiserumConcentrate for infusion1,000 units/doseSDL
Selenium SulfideTopical suspension2.5%SDL
Sennosides Tablet7.5 mgSDL
SertralineTablet50 mgSDL
Silicone CreamCreamDimethicone 10%, Chlorocresol 0.1%SDL
Simeticone Oral suspension100 mg/mLSDL
Simvastatin Tablet10 mg, 20 mgSDL
SirolimusTablet0.5 mg, 1 mg, 2 mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
SirolimusOral solution1 mg/mLMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral suspensionSodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mLSDL
Sodium BicarbonateInfusion4.2%, 8.4%SDL
Sodium BicarbonateInjection4.2%, 8.4%SDL
Sodium BicarbonateCapsule500 mgSDL
Sodium BicarbonatePowderMinimum 99%SDL
Sodium Bicarbonate & Sodium ChloridePowder9 parts Sodium Bicarbonate + 1 part Sodium ChlorideSDL
Sodium Calcium EdetateInjection200 mg/mLSDL
Sodium ChlorideInfusion0.45%, 0.9%, 3%, 20%SDL
Sodium ChlorideIrrigation solution0.9%SDL
Sodium ChlorideInjection0.45%, 0.9%, 3%, 20%SDL
Sodium ChlorideEye drops0.9%, 5%SDL
Sodium ChlorideEye ointment5%SDL
Sodium Chloride & Dextrose Sustained-release tabletSodium Chloride 500 mg + Dextrose 200 mg SDL
Sodium Chloride, Calcium Chloride Dihydrate & Potassium Chloride InfusionSodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/LSDL
Sodium Laurylsulfoacetate & Sodium Citrate EnemaSodium Laurylsulfoacetate 9 mg/mL + Sodium Citrate 90 mg/mL + Sorbitol 625 mg/mLSDL
Sodium NitriteInjection3%SDL
Sodium NitroprussideInjection10 mg/mL, 50mg/2ml SDL
Sodium Polystyrene SulfonateOral suspension15 g/60 mLSDL
Sodium Polystyrene SulfonatePowder for oral suspension99%SDL
Sodium Tetradecyl SulfateInjection1%, 3%SDL
Sodium ThiosulfateInjection25%SDL
Sodium ThiosulfateOral solution25%SDL
Sodium ThiosulfatePowder50 gSDL
Sodium ValproateControlled-release tablet200 mg, 300 mg, 500 mgSDL
Sodium ValproateEnteric-coated tablet200 mg SDL
Sodium ValproateInjection400 mgSDL
Sodium ValproateSyrup200 mg/5 mLSDL
Somatostatin (as Acetate) Infusion3 mgSDL
SomatropinPrefilled pen5 mg/1.5 mL, 10 mg/1.5 mLMAFTreatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature
SomatropinInjection3.33 mg, 4 mg, 6 mgMAFTreatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature
SpironolactoneTablet25 mgSDL
StreptokinaseInfusion1.5 million international unitsSDL
StreptomycinInjection1 g, 5 gSDL
Sulfadiazine SilverCream1%SDL
Sulfamethoxazole & TrimethoprimConcentrate for infusionSulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mLSDL
Sulfamethoxazole & TrimethoprimSuspensionTrimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mLSDL
Sulfamethoxazole & TrimethoprimTabletTrimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mgSDL
SulfasalazineEnteric-coated tablet500 mgSDL
Sulphur & Salicylic Acid CreamSulphur 4% + Salicylic Acid 2%SDL
Sulphur, Resorcinol & CalamineLotionSulphur 4% + Resorcinol 2% + Calamine 10%SDL
Sulphur, Zinc Oxide, Resorcinol & CalamineCreamSulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8%SDL
SulpirideTablet200 mgSDL
SumatriptanTablet50 mgSDL
Suxamethonium ChlorideInjection50 mg/mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
TacrolimusProlonged-release capsule0.5 mg, 1 mg, 5 mgSDL
TacrolimusCapsule0.5 mg, 1 mg, 5 mgSDL
Tacrolimus Ointment0.1%MAFTreatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
Tacrolimus Ointment0.03%MAF1) Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
2) Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids
TamoxifenTablet10 mg, 20 mgSDL
Temozolomide (generic)Capsule20 mg, 100 mgSDL
Tenofovir Disoproxil FumarateTablet 300 mgMAFTreatment of patients with chronic hepatitis B infection for whom nucleos(t)ide analogue therapy is indicated, whether treatment-naïve or experienced
TerazosinTablet2 mg, 5 mgSDL
Testosterone CipionateInjection100 mg/mLSDL
Tetanus Immunoglobulin (Human)Injection250 units/doseSDL
Tetanus Toxoid VaccineInjectionMinimum 40 international units/0.5 mLSDL
Tetracycline Hydrochloride Ointment3%SDL
Tetracycline Hydrochloride Capsule250 mgSDL
TheophyllineSustained-release tablet125 mg, 200 mg, 250 mg, 300 mgSDL
TheophyllineSyrup80 mg/15 mLSDL
TheophyllineTablet125 mgSDL
Thiamine Hydrochloride Injection100 mg/2 mL, 100 mg/mLSDL
Thiamine Hydrochloride Tablet10 mgSDL
Thiopental Sodium Injection0.5 g, 1 gSDL
ThrombinTopical solution5,000 international units/5 mLSDL
Ticlopidine Hydrochloride Tablet250 mgSDL
Timolol MaleateEye drops0.25%, 0.5%SDL
TioguanineTablet40 mgSDL
TolbutamideTablet500 mgSDL
Tolterodine Tartrate Extended-release capsule4 mgSDL
Tolterodine Tartrate Tablet1 mg, 2 mgSDL
TopiramateTablet25 mg, 50 mg, 100 mgSDL
Tramadol HydrochlorideCapsule50 mgSDL
Tramadol HydrochlorideTablet50 mgSDL
Tranexamic Acid Injection 100 mg/mLSDL
Tranexamic Acid Tablet500 mgSDL
TrastuzumabInfusion440 mgMAF1) Treatment of women with HER2-positive early breast cancer who are axillary lymph node positive
2) Treatment of women with HER2-positive early breast cancer with tumour size greater than 1 cm and are axillary lymph node negative
Checklist to be completed
3) Treatment of HER2-positive metastatic breast cancer, in the following circumstances:
In combination with a taxane for patients who have not received chemotherapy for their metastatic disease, or
In combination with an aromatase inhibitor for postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab
TretinoinCapsule10 mgSDL
Triamcinolone AcetonideInjection10 mg/mLSDL
Triamcinolone AcetonideNasal spray55 mcg/doseSDL
Triamterene & Hydrochlorothiazide TabletTriamterene 50 mg + Hydrochlorothiazide 25 mgSDL
TrifluoperazineTablet1 mg, 5 mgSDL
TrimethoprimOral suspension50 mg/5 mLSDL
TrimethoprimTablet100 mgSDL
TropicamideEye drops0.5%, 1% SDL
TropicamideSingle-use eye drops1%SDL
Typhoid Vaccine (salmonella typhi Vi polysaccharide Ty2 strain) (Killed vaccine)Injection25 mcg/0.5 mLSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Umeclidinium Powder inhaler62.5 mcg/doseSDL
Umeclidinium & VilanterolPowder inhalerUmeclidinium 62.5 mcg/dose + Vilanterol 25 mcg/doseSDL
UreaCream5%, 10% SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
ValganciclovirTablet450 mgSDLPrevention of cytomegalovirus infection after solid organ transplant
ValsartanTablet80 mg, 160 mgSDL
VancomycinInfusion500 mgSDL
Vasopressin Injection20 pressor units/mLSDL
VenlafaxineExtended-release capsule75 mg, 150 mgSDL
Verapamil HydrochlorideInjection2.5 mg/mLSDL
Verapamil HydrochlorideTablet40 mgSDL
Vinblastine SulfateInjection10 mgSDL
Vincristine SulfateInjection1 mgSDL
Vitamin ACapsule10,000 unitsSDL
Vitamin B ComplexInjectionThiamine Hydrochloride 10 mg/2 mL + Sodium Riboflavin Phosphate 4 mg/2 mL + Nicotinic Acid 40 mg/2 mL + Panthenol 6 mg/2 mL + Biotin 5 mg/2 mL + Pyridoxine Hydrochloride 4 mg/2 mL + Cyanocobalamin 8 mcg/2 mLSDL
Vitamin B ComplexTabletThiamine 3 mg + Riboflavine 1.5 mg + Nicotinamide 10 mg + Pyridoxine 0.5 mgSDL
Voriconazole Infusion200 mgMAF1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole Oral suspension40 mg/mLMAF1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole Tablet50 mg, 200 mgMAF1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Warfarin SodiumTablet1 mg, 3 mg, 5 mgSDL
White Soft ParaffinOintment-SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Yellow Fever Virus Vaccine (live-attenuated)InjectionMinimum 1,000 LD50 unitsSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Zoledronic AcidInfusion5 mg/100 mLMAF1) For patients with osteoporosis (T score ≤ -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
2) For patients with FRAX of ≥ 20 for major osteoporotic fractures and ≥ 3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Zoledronic AcidInfusion4 mgMAF1) Treatment of metastatic bone lesions from solid tumours and multiple myeloma
2) Treatment of hypercalcaemia of malignancy
Zuclopenthixol AcetateInjection50 mg/mLSDL
Zuclopenthixol DecanoateInjection200 mg/mLSDL